Amicus Therapeutics, Inc. (NASDAQ:FOLD)
CAPS Rating:
A clinical-stage biopharmaceutical company, which focused on the discovery, development and commercialization of novel small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases.
RSS Headlines
Fool UK
Recs
Hearing & reading very positive reports on this relatively new (recent IPO)Pharma stock!
Great time to get on the ground-floor of a potential ground-breaking pharmaceutical opportunity.
Should be be hearing good reports from analysts very soon, which will be stock/eye popping time.